CDW Holding Limited, listed on the SGX Mainboard, has announced promising preclinical results for its next-generation drug delivery technology, LNP-LANFA. Developed in collaboration with Neoregen Biotech, the technology showed significant improvements in targeting the spleen and reducing immunogenicity in animal studies. This advancement could address the challenges of immunogenicity and hepatotoxicity associated with conventional lipid nanoparticles (LNPs).
The animal studies, conducted by WOOJUNG BIO in South Korea, revealed that LNP-LANFA achieved a 3.4-fold increase in spleen targeting compared to traditional LNPs, whilst reducing liver accumulation by 62%. This is particularly beneficial for therapies requiring efficient delivery to immune cells, such as vaccines and cancer immunotherapies. Additionally, tests conducted by Kobe Gakuin University confirmed the technology’s low immunogenicity, suggesting its suitability for repeated administration.
CDW plans to commercialise LNP-LANFA globally, with efforts to secure early licensing deals at the BIO International Convention in June. The company has filed a provisional patent application to protect its intellectual property and intends to engage with major pharmaceutical companies for potential partnerships.
Chairman and CEO of CDW, Kato Tomonori, stated, “These animal study results are exactly the kind of data that the pharmaceutical industry has been eagerly awaiting. By overcoming the shortcomings of current technologies and achieving both a 3.4-fold shift towards the spleen and low immunogenicity comparable to saline, LNP-LANFA demonstrates a clear advantage as a next-generation drug delivery platform.”
With the global LNP market projected to grow significantly, CDW is optimistic that LNP-LANFA will become a key revenue driver, enhancing the company’s corporate value.
